Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

MDGL

Madrigal Pharmaceuticals Inc

Jun 18 • 04:00PM ET

276.01

Dollar change -0.71
Percentage change -0.26	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IWM XBI VBR VXF IWO IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-23.08	Insider Own	17.75%	Shs Outstand	19.88M	Perf Week	-5.47%
Market Cap	5.88B	Forward P/E	-	EPS next Y	-17.94	Insider Trans	-6.89%	Shs Float	17.53M	Perf Month	25.42%
Income	-444.27M	PEG	-	EPS next Q	-7.51	Inst Own	96.84%	Short Float	29.83%	Perf Quarter	3.89%
Sales	0.00M	P/S	-	EPS this Y	-42.98%	Inst Trans	-1.64%	Short Ratio	10.58	Perf Half Y	16.40%
Book/sh	42.80	P/B	6.45	EPS next Y	37.25%	ROA	-62.81%	Short Interest	5.23M	Perf Year	13.08%
Cash/sh	49.70	P/C	5.55	EPS next 5Y	0.00%	ROE	-88.78%	52W Range	119.76 - 299.98	Perf YTD	19.29%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-55.24%	ROI	-45.90%	52W High	-7.99%	Beta	-0.43
Dividend TTM	-	Quick Ratio	9.39	Sales past 5Y	0.00%	Gross Margin	-	52W Low	130.47%	ATR (14)	14.59
Dividend Ex-Date	-	Current Ratio	9.39	EPS Y/Y TTM	-27.58%	Oper. Margin	0.00%	RSI (14)	65.46	Volatility	4.06% 6.24%
Employees	376	Debt/Eq	0.14	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.44	Target Price	365.07
Option/Short	Yes / Yes	LT Debt/Eq	0.14	EPS Q/Q	-74.47%	Payout	-	Rel Volume	0.62	Prev Close	276.72
Sales Surprise	-	EPS Surprise	-17.42%	Sales Q/Q	-	Earnings	May 07 BMO	Avg Volume	494.13K	Price	276.01
SMA20	11.36%	SMA50	19.60%	SMA200	32.22%	Trades		Volume	308,366	Change	-0.26%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-11-24	Initiated	Wolfe Research	Outperform	$382
Apr-22-24	Initiated	BofA Securities	Underperform	$150
Mar-15-24	Upgrade	B. Riley Securities	Sell → Neutral	$155 → $270
Mar-06-24	Initiated	Citigroup	Buy	$382
Feb-26-24	Downgrade	B. Riley Securities	Neutral → Sell	$155
Dec-20-22	Reiterated	Oppenheimer	Outperform	$170 → $250
Dec-19-22	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-22	Reiterated	Piper Sandler	Overweight	$203 → $280
Dec-19-22	Reiterated	H.C. Wainwright	Buy	$170 → $225
Jul-08-22	Downgrade	B. Riley Securities	Buy → Neutral	$131 → $75
Oct-07-21	Initiated	Jefferies	Buy	$151
Aug-06-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
May-20-21	Resumed	Goldman	Buy	$195
Nov-24-20	Resumed	Evercore ISI	Outperform	$180
Nov-06-20	Reiterated	H.C. Wainwright	Buy	$165 → $184
Jul-31-20	Initiated	Piper Sandler	Overweight	$208
Jun-05-20	Initiated	BMO Capital Markets	Market Perform	$135
May-05-20	Initiated	Chardan Capital Markets	Buy	$205
Jan-30-20	Initiated	Canaccord Genuity	Buy	$198
Jan-09-20	Upgrade	UBS	Neutral → Buy	$125 → $127

Show Previous Ratings

Jun-16-24 12:05PM	Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word. (Motley Fool)
Jun-15-24 09:45AM	Where Will Madrigal Pharmaceuticals Be in 3 Years? (Motley Fool)
Jun-12-24 03:56PM	Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily)
Jun-10-24 09:45AM	Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals (Motley Fool)
Jun-06-24 08:00AM	Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) Presented at the EASL Congress (GlobeNewswire)
Jun-05-24 04:10PM	Madrigal, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH (Investor's Business Daily)
03:17PM	What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? (Benzinga)
10:56AM	Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH (Investor's Business Daily)
08:00AM	Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-29-24 08:00AM	Madrigal Pharmaceuticals to Present Multiple Rezdiffra (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress (GlobeNewswire)
May-24-24 03:17AM	Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, Chief Pharmaceutical ... (GuruFocus.com)
May-21-24 09:45AM	Is Madrigal Pharmaceuticals Stock a Buy? (Motley Fool)
May-17-24 03:08AM	Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing (MT Newswires)
May-15-24 09:19PM	John Paulson's Strategic Moves in Q1 2024 Highlight Madrigal Pharmaceuticals' Prominent Role (GuruFocus.com)
May-10-24 08:51AM	B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating (MT Newswires)
May-09-24 10:53AM	UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating (MT Newswires)
May-08-24 01:23PM	Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:02AM	Madrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-07-24 09:18AM	Sector Update: Health Care Stocks Steady Pre-Bell Tuesday (MT Newswires) -7.48%
08:34AM	Madrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra Launch (GuruFocus.com)
08:08AM	Madrigal Pharmaceuticals Q1 Loss Widens; Shares Fall Pre-Bell (MT Newswires)
07:17AM	Madrigal: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-24-24 04:00PM	Madrigal Statement on the Passing of Dr. Stephen Harrison (GlobeNewswire) -6.29% -5.02%
Apr-23-24 08:00AM	Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 (GlobeNewswire)
Apr-22-24 06:00AM	6 Stocks Positioned to Soar as Investors Focus on MASH (News Direct)
Apr-16-24 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-15-24 04:28PM	Latest Insider Selling in April 2024: 10 Stocks to Watch (Insider Monkey)
Apr-09-24 08:00AM	Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis (GlobeNewswire)
Apr-05-24 07:15AM	Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics (Motley Fool)
Apr-04-24 01:55AM	Madrigal Pharmaceuticals Inc Director James Daly Sells 32,489 Shares (GuruFocus.com)
01:54AM	Madrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Shares (GuruFocus.com)
01:54AM	Madrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Shares (GuruFocus.com)
Apr-03-24 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:45AM	1 No-Brainer Growth Stock to Buy Now (Motley Fool)
Apr-01-24 09:09PM	The 3 Best Biotech Stocks to Buy in April 2024 (InvestorPlace)
09:59AM	ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 09:00AM	Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals (Motley Fool)
04:43AM	Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? (Motley Fool)
Mar-26-24 09:53AM	Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock (Motley Fool)
Mar-22-24 06:15AM	This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy? (Motley Fool)
Mar-19-24 05:50AM	Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? (Motley Fool) -6.20%
Mar-18-24 11:58PM	Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering (GlobeNewswire)
08:01PM	7 Biotech Stocks Ready to Ride the Sectors Resurgence (InvestorPlace)
04:47PM	UPDATE 1-Madrigal plans $500 million fund raising to prepare for NASH drug launch (Reuters)
04:12PM	Madrigal commences $500 million public offering of common stock (Reuters)
04:04PM	Madrigal Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
03:15PM	Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark (Investor's Business Daily)
07:00AM	Ozempic Cant Do It AllA Potential New Blockbuster Is a Reminder of That (The Wall Street Journal)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
05:50AM	Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? (Motley Fool)
Mar-15-24 04:35PM	Wegovy and Zepbound Cast Shadow Over Madrigals Liver Drug (Barrons.com) +11.00%
04:14PM	Madrigal Stock Soars 11% After FDA Approved The First MASH Treatment (Investor's Business Daily)
03:50PM	Geron, Madrigal Pharmaceuticals jump on good news from FDA (Yahoo Finance Video)
02:34PM	Madrigal Pharmaceuticals Stock Surges After FDA Approves Liver Disease Treatment (The Wall Street Journal)
01:45PM	Madrigal Pharmaceuticals Soars After Getting FDA Approval for Liver-Scarring Treatment (Investopedia)
12:56PM	Top Stock Movers Now: Adobe, Ulta Beauty, Jabil, and More (Investopedia)
12:09PM	US STOCKS-Wall St slides as inflation woes dampen rate-cut bets (Reuters)
10:17AM	MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today (InvestorPlace)
10:01AM	Madrigal Can Market the First Drug for Obesity-Scarred Livers. The Stock Soars. (Barrons.com)
09:30AM	Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH (Zacks)
07:45AM	Madrigal Stock Soars More Than 25% After FDA Approved First In MASH Treatment (Investor's Business Daily)
05:35AM	Madrigal, FDA approval in hand, outlines plan to sell MASH drug (BioPharma Dive)
Mar-14-24 04:25PM	Why Madrigal Stock, Which Has Gained 62% In A Month, Just Slumped Ahead Of A Potential First-Ever In MASH (Investor's Business Daily) -10.77%
04:15PM	Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis (GlobeNewswire)
12:11PM	Madrigal wins FDA approval of first drug for MASH (BioPharma Dive)
Mar-09-24 05:52AM	Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon. (Motley Fool)
Mar-06-24 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-24 08:00AM	Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis (GlobeNewswire)
06:03AM	1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247? (Motley Fool)
Feb-28-24 07:01AM	Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer (GlobeNewswire) +6.02%
07:00AM	Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
06:45AM	Madrigal: Q4 Earnings Snapshot (Associated Press Finance)
Feb-26-24 04:04PM	Weight-Loss Tizzy: Why Altimmune Surged 23% As Others Tumbled On A New Study (Investor's Business Daily)
10:52AM	Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena (Investor's Business Daily)
Feb-23-24 05:43AM	1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street (Motley Fool)
Feb-21-24 08:00AM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-13-24 01:36PM	15 Best Strong Buy Stocks To Invest In (Insider Monkey) -5.33%
Feb-08-24 08:00AM	Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine (GlobeNewswire) -9.11%
Feb-06-24 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.28% -6.40%
11:29AM	Why Eli Lilly Deserves to Unseat Tesla Among the Magnificent Seven (The Wall Street Journal)
11:28AM	Madrigal Pharmaceuticals Stock Shows Rising Relative Strength (Investor's Business Daily)
Jan-29-24 08:00AM	Madrigal Pharmaceuticals Announces Additions to Its Leadership Team (GlobeNewswire)
02:59AM	2 Rising Biotechs That Could Become the Next Novo Nordisk (Motley Fool)
Jan-22-24 08:00AM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:29AM	2 Stocks That Could Soar This Year: Are They Buys? (Motley Fool)
Jan-04-24 08:00AM	Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference (GlobeNewswire)
01:21AM	5 FDA decisions to watch in the first quarter (BioPharma Dive)
Jan-03-24 04:30PM	Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.58%
Dec-30-23 06:50AM	3 Stocks That Could Be Monster Winners in 2024 (Motley Fool)
Dec-22-23 04:30PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.74%
Dec-19-23 01:02PM	Senior VP Robert Waltermire Sells 4,000 Shares of Madrigal Pharmaceuticals Inc (MDGL) (GuruFocus.com)
10:16AM	11 Stocks Insiders and Billionaires Are Crazy About (Insider Monkey)
Dec-15-23 11:01PM	Insider Sell Alert: Senior VP Robert Waltermire Sells 3,800 Shares of Madrigal Pharmaceuticals Inc (GuruFocus.com)
Dec-07-23 08:45AM	These 2 Stocks Could Be About to Soar: Are They Buys? (Motley Fool)
Nov-27-23 04:30PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:50AM	11 Best Upside Stocks To Buy Right Now (Insider Monkey)
Nov-24-23 10:00AM	Kinnate Biopharma, Madrigal Pharma, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-21-23 08:00AM	Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer (GlobeNewswire)
Nov-17-23 10:46AM	Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating (Investor's Business Daily)

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 14 '24	Option Exercise	87.09	1,900	165,471	7,400	Jun 18 09:39 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 14 '24	Sale	280.00	1,900	532,000	5,500	Jun 18 09:39 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 12 '24	Option Exercise	87.92	2,000	175,840	7,500	Jun 14 09:44 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 12 '24	Sale	285.00	2,000	570,000	5,500	Jun 14 09:44 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	May 21 '24	Sale	231.34	1,036	239,668	5,500	May 23 09:36 PM
CRAVES FRED B	Director	May 14 '24	Option Exercise	103.02	22,489	2,316,844	435,851	May 16 09:53 PM
CRAVES FRED B	Director	May 14 '24	Sale	212.88	22,489	4,787,404	413,362	May 16 09:53 PM
FRIEDMAN PAUL A	Director	Apr 08 '24	Option Exercise	9.45	26,270	248,251	212,005	Apr 10 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 08 '24	Option Exercise	9.45	2,676	25,288	461,675	Apr 10 08:53 PM
FRIEDMAN PAUL A	Director	Apr 08 '24	Sale	246.19	26,270	6,467,491	185,735	Apr 10 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 08 '24	Sale	245.99	2,676	658,258	458,999	Apr 10 08:53 PM
FRIEDMAN PAUL A	Director	Apr 05 '24	Option Exercise	9.45	27,613	260,943	213,348	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 05 '24	Option Exercise	9.45	27,506	259,932	486,505	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 05 '24	Sale	243.40	27,613	6,721,081	185,735	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 05 '24	Sale	243.36	27,506	6,693,790	458,999	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 04 '24	Option Exercise	9.45	18,710	176,810	204,445	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 04 '24	Option Exercise	9.45	18,537	175,175	477,536	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 04 '24	Sale	242.96	18,710	4,545,721	185,735	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 04 '24	Sale	242.91	18,537	4,502,823	458,999	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 03 '24	Option Exercise	9.45	27,845	263,135	486,844	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 03 '24	Option Exercise	9.45	27,407	258,996	213,142	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 03 '24	Sale	245.14	27,845	6,825,976	458,999	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 03 '24	Sale	245.12	27,407	6,718,002	185,735	Apr 05 08:50 PM
BATE KENNETH	Director	Apr 02 '24	Option Exercise	105.08	11,212	1,178,157	12,410	Apr 03 08:44 PM
Daly James M	Director	Apr 02 '24	Option Exercise	105.08	10,912	1,146,633	12,110	Apr 03 08:41 PM
BATE KENNETH	Director	Apr 02 '24	Sale	244.49	11,212	2,741,219	1,198	Apr 03 08:44 PM
Daly James M	Director	Apr 02 '24	Sale	244.51	10,912	2,668,087	1,198	Apr 03 08:41 PM
Daly James M	Director	Apr 01 '24	Option Exercise	100.79	21,577	2,174,711	22,775	Apr 03 08:41 PM
BATE KENNETH	Director	Apr 01 '24	Option Exercise	57.96	21,277	1,233,187	22,475	Apr 03 08:44 PM
Levy Richard S	Director	Apr 01 '24	Option Exercise	63.92	11,000	703,160	21,298	Apr 03 08:47 PM
Daly James M	Director	Apr 01 '24	Sale	257.24	21,577	5,550,544	1,198	Apr 03 08:41 PM
BATE KENNETH	Director	Apr 01 '24	Sale	257.26	21,277	5,473,779	1,198	Apr 03 08:44 PM
Levy Richard S	Director	Apr 01 '24	Sale	257.48	11,000	2,832,335	10,298	Apr 03 08:47 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 15 '23	Option Exercise	87.92	2,000	175,840	7,667	Dec 18 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 15 '23	Sale	238.50	2,000	477,000	5,667	Dec 18 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 14 '23	Option Exercise	87.92	2,000	175,840	7,667	Dec 18 04:30 PM
BAKER BROS. ADVISORS LP	Director	Dec 14 '23	Buy	228.32	20,633	4,710,893	1,793,403	Dec 14 06:10 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 14 '23	Sale	232.50	2,000	465,000	5,667	Dec 18 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 13 '23	Option Exercise	87.92	2,500	219,800	8,167	Dec 14 04:30 PM
BAKER BROS. ADVISORS LP	Director	Dec 13 '23	Buy	219.39	81,159	17,805,684	1,774,294	Dec 14 06:10 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 13 '23	Sale	225.40	2,500	563,500	5,667	Dec 14 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 12 '23	Option Exercise	87.92	1,300	114,296	6,967	Dec 14 04:30 PM
BAKER BROS. ADVISORS LP	Director	Dec 12 '23	Buy	218.31	34,578	7,548,616	1,699,129	Dec 14 06:09 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 12 '23	Sale	217.85	1,300	283,200	5,667	Dec 14 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 05 '23	Option Exercise	87.09	1,000	87,090	16,001	Dec 06 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 05 '23	Sale	227.33	1,000	227,330	15,001	Dec 06 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 04 '23	Option Exercise	81.16	1,800	146,090	16,801	Dec 06 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 04 '23	Sale	218.87	1,800	393,964	15,001	Dec 06 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 30 '23	Option Exercise	73.75	3,000	221,250	18,001	Dec 01 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 30 '23	Sale	204.58	3,000	613,730	15,001	Dec 01 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 29 '23	Option Exercise	73.75	4,000	295,000	19,001	Dec 01 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 29 '23	Sale	199.19	4,000	796,750	15,001	Dec 01 04:30 PM
BAKER BROS. ADVISORS LP	Director	Nov 21 '23	Buy	188.47	64,350	12,128,340	1,667,104	Nov 21 06:15 PM
BAKER BROS. ADVISORS LP	Director	Nov 20 '23	Buy	185.74	20,709	3,846,575	1,607,668	Nov 21 06:14 PM
BAKER BROS. ADVISORS LP	Director	Nov 17 '23	Buy	174.70	46,370	8,100,704	1,588,541	Nov 21 06:14 PM
BAKER BROS. ADVISORS LP	Director	Nov 15 '23	Buy	161.97	15,199	2,461,721	1,545,775	Nov 15 05:13 PM
BAKER BROS. ADVISORS LP	Director	Nov 14 '23	Buy	154.00	37,660	5,799,653	1,500,227	Nov 15 05:12 PM
BAKER BROS. ADVISORS LP	Director	Nov 14 '23	Buy	156.42	34,188	5,347,837	1,531,757	Nov 15 05:13 PM
BAKER BROS. ADVISORS LP	Director	Nov 13 '23	Buy	143.21	69,839	10,001,368	1,465,494	Nov 15 05:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MDGL

Madrigal Pharmaceuticals Inc

Upgrade your FINVIZ experience